Scarica l'app Stockscreener
4.755
7.67%
-0.395
Dopo l'orario di chiusura:
4.72
-0.035
-0.74%
Aquestive Therapeutics Inc Borsa (AQST) Ultime notizie
Aquestive: Rare Opportunity With Dual Platform Strategy (NASDAQ:AQST) - Seeking Alpha
Aquestive Therapeutics (NASDAQ:AQST) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Aquestive Therapeutics: Q3 Earnings Snapshot - mySA
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Aquestive Therapeutics reports Q3 EPS (13c), consensus (13c) - TipRanks
AQSTAquestive Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Aquestive Therapeutics Optimistic Financial and Strategic Outlook - TipRanks
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Aquestive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aquestive Therapeutics Inc (AQST) Q3 2024: Everything You Need T - GuruFocus.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $8.83 Consensus Target Price from Brokerages - MarketBeat
Learn to Evaluate (AQST) using the Charts - Stock Traders Daily
Aquestive Therapeutics (NASDAQ:AQST) Price Target Raised to $13.00 - Defense World
Aquestive Therapeutics (AQST) Set to Announce Quarterly Earnings on Monday - MarketBeat
Leerink raises Aquestive Therapeutics stock PT on 'top-line' study results - Investing.com Canada
Aquestive Therapeutics to Present Subsequent Analysis of - GlobeNewswire
Leerink Partners Raises Aquestive Therapeutics (NASDAQ:AQST) Price Target to $13.00 - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Aquestive Therapeutics’ Breakthrough in Allergy Treatment Study - Yahoo Finance
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American - GlobeNewswire
Institutions profited after Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) market cap rose US$51m last week but individual investors profited the most - Simply Wall St
Aquestive Therapeutics' SWOT analysis: stock poised for growth as Anaphylm nears FDA submission - Investing.com Australia
Aquestive Therapeutics Pushes Retail Sentiment Into ‘Extremely Bullish’ Zone On OAS Drug Trial Success - Barchart
Aquestive Therapeutics' SWOT analysis: stock poised for growth as Anaphylm nears FDA submission By Investing.com - Investing.com South Africa
Aquestive Therapeutics Inc (AQST) Has Recovered 74.67% From Its Low: Is This The Beginning Of A Trend? - Stocks Register
Aquestive Therapeutics Announces Positive Topline Results - GlobeNewswire
Aquestive Therapeutics a new overweight at Piper on oral film products - MSN
Aquestive Therapeutics to Report Third Quarter 2024 - GlobeNewswire
Aquestive Therapeutics updates bylaws, shortens nomination look-back By Investing.com - Investing.com South Africa
Aquestive Therapeutics updates bylaws, shortens nomination look-back - Investing.com India
Investing in Aquestive Therapeutics Inc (AQST) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Financial Snapshot: Analyzing Aquestive Therapeutics Inc (AQST)’s Key Ratio Metrics - The Dwinnex
Top investors say Aquestive Therapeutics Inc (AQST) ticks everything they need - SETE News
Aquestive Therapeutics (NASDAQ:AQST) Given "Market Outperform" Rating at JMP Securities - MarketBeat
In the Green: Aquestive Therapeutics Inc (AQST) Closes at 4.85, Up/Down -2.02 from Previous Day - The Dwinnex
Should investors be concerned about Aquestive Therapeutics Inc (AQST)? - US Post News
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $8.67 Average Price Target from Brokerages - MarketBeat
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Position Trimmed by Renaissance Technologies LLC - MarketBeat
A better buy-in window may exist right now for Aquestive Therapeutics Inc (AQST) - SETE News
Can you now get a good deal on Aquestive Therapeutics Inc’s shares? - US Post News
Aquestive Therapeutics stock target lifted, rating held on product pipeline By Investing.com - Investing.com Canada
aquestiveinvestordayreca.htm - SEC.gov
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate - AOL
Trading Day Review: Aquestive Therapeutics Inc (AQST) Loses Momentum, Closing at 4.72 - The Dwinnex
AQST’s Stock Tango: The Dance of Gains and Losses in 2023 - The InvestChronicle
Aquestive Therapeutics (NASDAQ:AQST) Earns "Market Outperform" Rating from JMP Securities - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Price Target Raised to $10.00 - MarketBeat
146,155 Shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Purchased by Deerfield Management Company L.P. Series C - MarketBeat
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day - GlobeNewswire
Aquestive advances epinephrine treatments, completes study By Investing.com - Investing.com South Africa
Wall Street SWOT: Aquestive Therapeutics stock poised for potential breakthrough - Investing.com
Aquestive advances epinephrine treatments, completes study - Investing.com
Aquestive Therapeutics Showcases Innovations and Market Strategy - TipRanks
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual ... - The Bakersfield Californian
0.88%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):